Padua Prediction Score for VTE Risk
Estimates VTE risk in hospitalised medical patients to guide thromboprophylaxis decisions.
Score interpretation
Padua < 4: Low risk (~0.3% VTE rate). Pharmacological prophylaxis not routinely required.
→ Mechanical prophylaxis (TED stockings, pneumatic compression). Encourage early mobilisation. Reassess daily.
Padua ≥ 4: High risk (~11% VTE rate). Pharmacological prophylaxis indicated.
→ Start LMWH (enoxaparin 40mg SC OD) unless contraindicated. Adjust dose in renal impairment. Assess bleeding risk (IMPROVE Bleeding Score).
Interpretation bands for the Padua Score. Apply clinical judgement and local guidance.
References
- Barbar S, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8(11):2450–2457.
Related
Curated clinical cross-links plus same-class fallbacks.
- Enoxaparin (LMWH) · Anticoagulant
- Enoxaparin · Low Molecular Weight Heparin (LMWH)
- Enoxaparin sodium · Low molecular weight heparin (LMWH)
- Dalteparin sodium · Low molecular weight heparin (LMWH)
- Bemiparin sodium · Low molecular weight heparin (LMWH)
- Enoxaparin (VTE in Pregnancy) · Low Molecular Weight Heparin (LMWH) — VTE Prophylaxis/Treatment
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.